2-花生四烯酰-1-棕榈酰-sn-甘油-3-磷酸胆碱 | 35418-58-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 中文名称: 2-花生四烯酰-1-棕榈酰-sn-甘油-3-磷酸胆碱
• 中文别名: 2-花生四烯酰基-1-棕榈酰基-sn-甘油-3-磷酸胆碱
• 英文名称: PAPC
• 英文别名: 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine；PC (16:0/20:4)；PC(16:0/20:4(5Z,8Z,11Z,14Z))；[(2R)-3-hexadecanoyloxy-2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 35418-58-7
• 化学式: C₄₄H₈₀NO₈P
• 分子量: 782.095
• InChiKey: IIZPXYDJLKNOIY-JXPKJXOSSA-N

物化性质

• 溶解度：
  氯仿：可溶
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  12.6
• 重原子数：
  54
• 可旋转键数：
  40
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  111
• 氢给体数：
  0
• 氢受体数：
  8

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  2-花生四烯酰-1-棕榈酰-sn-甘油-3-磷酸胆碱 在 偶氮二异庚腈 作用下， 以 叔丁醇 为溶剂， 反应 6.0h， 生成 、
  参考文献：
  名称：

  Positional Isomers of Monohydroperoxides Produced by Peroxidation of Phosphatidylcholine Containing an Arachidonoyl Moiety in a Liposomal Suspension

  摘要：

  脂质体悬浮液中 1-棕榈酰-2-花生四烯酰-磷脂酰胆碱 (PC-AA) 过氧化产生的单氢过氧化物具有特征性的异构体组成。在衍生自戊二烯基中间体的两种可能的异构体中，羧基末端带有氢过氧基的异构体的水平明显低于另一种异构体。

  DOI：

  10.1271/bbb.63.1308
• 作为产物：
  描述：

  花生四烯酸 在 4-二甲氨基吡啶 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 102.0h， 生成 2-花生四烯酰-1-棕榈酰-sn-甘油-3-磷酸胆碱
  参考文献：
  名称：

  Synthesis of a Small Library of Mixed-Acid Phospholipids from D-Mannitol as a Homochiral Starting Material.

  摘要：

  描述了一种使用新保护策略合成一系列含有多不饱和脂肪酸的混酸磷脂。具体而言，分别用BCl3和354 nm的光去除的保护基团是苄基和甲基α-(2, 4-二硝基苯基)乙酸。

  DOI：

  10.1248/cpb.47.1659

文献信息

• [EN] PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO<br/>[FR] ANTAGONISTES DU RÉCEPTEUR EP2 DES PROSTAGLANDINES, DÉRIVÉS, COMPOSITIONS ET UTILISATIONS ASSOCIÉS
  申请人：UNIV EMORY

  公开号：WO2015167825A1

  公开（公告）日：2015-11-05

  The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.

  该披露涉及前列腺素受体EP2拮抗剂，衍生物，组合物以及相关方法。在某些实施例中，该披露涉及治疗或预防EP2受体激活在生理作用中起作用的疾病和疾病的方法，例如但不限于脑损伤，炎症性疾病，癫痫后的神经炎症，疼痛，子宫内膜异位症，癌症，类风湿性关节炎，皮肤炎症，血管炎症，结肠炎和神经系统疾病，通过向需要的受试者给予包含本文所披露的化合物的药物组合物进行治疗。
• Preparation and Characterization of 8a-(Phosphatidylcholine-dioxy)- α-tocopherones and their Formation during the Peroxidation of Phosphatidylcholine in Liposomes
  作者：Ryo YAMAUCHI、Hiromi MIZUNO、Koji KATO

  DOI：10.1271/bbb.62.1293

  日期：1998.1

  α-Tocopherol was reacted with the phosphatidylcholines (PCs), 1-palmitoyl-2-linoleoyl-3-sn-PC (PLPC), 1-palmitoyl-2-linolenoyl-3-sn-PC, 1-palmitoyl-2-arachidonoyl-3-sn-PC (PAPC) and 1-stearoyl-2-arachidonoyl-3-sn-PC, in the presence of the free radical initiator, 2,2′-azobis(2,4-dimethylvaleronitrile), at 37°C. The addition products of α-tocopherol with the PC peroxyl radicals were isolated and identified as 8a-(PC-dioxy)-α-tocopherones, in which the peroxyl radicals derived from each PC molecule attacked the 8a-position of the α-tocopheroxyl radical. The antioxidative efficiency of α-tocopherol against the peroxidation of PLPC and PAPC in liposomes was assessed by the formation of the reaction products of α-tocopherol. When α-tocopherol was oxidized in the presence of the water-soluble free radical initiator, 2,2′-azobis(2-amidinopropane) dihydrochloride, epoxy-α-tocopherylquinones were mainly produced together with 8a-(PC-dioxy)-α-tocopherones and α-tocopherylquinone. The yield of α-tocopherylquinone was increased by treating each sample with dilute acid which indicates the presence of tocopherone precursors other than the 8a-(PC-dioxy)-α-tocopherones. The same products were also detected from iron-dependent peroxidation, although the yields were very low.

  在自由基存在的情况下，α-生育酚与磷脂酰胆碱（PC）、1-棕榈酰-2-亚油酰-3-sn-PC（PLPC）、1-棕榈酰-2-亚麻酸酰-3-sn-PC（PAPC）和 1-硬脂酰-2-丙烯酰-3-sn-PC（PLPC）发生反应、在自由基引发剂 2,2′-偶氮双（2,4-二甲基戊腈）的作用下，于 37°C 加入 1-棕榈酰-2-丙烯酰-3-sn-PC（PAPC）和 1-硬脂酰-2-丙烯酰-3-sn-PC。经分离鉴定，α-生育酚与 PC 过氧化自由基的加成产物为 8a-（PC-二氧）-α-生育酚酮，其中每个 PC 分子产生的过氧自由基攻击α-生育酚自由基的 8a 位。通过α-生育酚反应产物的形成，评估了α-生育酚对脂质体中PLPC和PAPC过氧化反应的抗氧化效率。当α-生育酚在水溶性自由基引发剂2,2′-偶氮双（2-脒基丙烷）二盐酸盐存在下被氧化时，主要生成环氧-α-生育酚醌和8a-（PC-二氧）-α-生育酚酮以及α-生育酚醌。用稀酸处理每个样品后，α-生育醌的产量都有所增加，这表明除了 8a-（PC-二氧）-α-生育酚酮外，还存在生育酚酮前体。在铁依赖性过氧化反应中也检测到了相同的产物，不过产量很低。
• Functional associative coatings for nanoparticles
  申请人：Hainfeld James F.

  公开号：US20080089836A1

  公开（公告）日：2008-04-17

  Described herein are nanoparticles that are coated with a bilayer of molecules formed from surface binding molecules and amphiphatic molecules. The bilayer coating self assembles on the nanoparticles from readily available materials/molecules. The modular design of the bilayer coated nanoparticles provides a means for readily and efficiently optimizing the properties of the bilayer coated nanoparticle compositions. Also described herein are uses of such nanoparticles in medicine, laboratory techniques, industrial and commerical applications.

  本文描述了一种纳米颗粒，其表面涂覆有由表面结合分子和两亲分子形成的双层分子层。该双层涂层可以自组装在纳米颗粒上，使用易得的材料/分子。双层涂层纳米颗粒的模块化设计提供了一种方便和高效地优化其性质的方法。此外，本文还描述了这种纳米颗粒在医学、实验室技术、工业和商业应用中的用途。
• COMPOSITION AND METHOD FOR CONVERTING A NON-PATHOGENIC PRION PROTEIN INTO A PATHOGENIC CONFORMATION AND USES THEREOF
  申请人：Ma Jiyan

  公开号：US20110183421A1

  公开（公告）日：2011-07-28

  Described herein is a composition for converting a non-pathogenic prion protein (“PrP N ”) into a prion protein in a pathogenic conformation (“PrP Path ”) comprising a lipid and a polyanion. Also described are methods of (1) using the composition to convert a PrP N to a PrP Path , (2) identifying a potential therapeutic substance affecting PrP Path , and (3) diagnosing PrP Path infection in a subject using the composition and at least one cycle of protein misfolding cyclic amplification.

  本文描述了一种将非致病性朊蛋白质（“PrPN”）转化为致病构象的朊蛋白质（“PrPPath”）的组合物，包括脂质和多聚阴离子。还描述了使用该组合物进行以下方法的方法：（1）将PrPN转化为PrPPath，（2）鉴定影响PrPPath的潜在治疗物质，以及（3）使用该组合物和至少一个蛋白质错配循环扩增周期诊断主体中的PrPPath感染。
• PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO
  申请人：Jiang Jianxiong

  公开号：US20140179750A1

  公开（公告）日：2014-06-26

  The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.

  本公开涉及前列腺素受体EP2拮抗剂、衍生物、组合物及相关方法。在某些实施例中，本公开涉及通过向需要治疗或预防EP2受体激活在生理作用中的疾病和病症，例如但不限于脑损伤、炎症性疾病、癫痫后神经炎症、疼痛、子宫内膜异位症、癌症、类风湿性关节炎、皮肤炎症、血管炎症、结肠炎和神经系统疾病的受试者中，通过给予含有本文所披露的化合物的制药组合物来进行治疗的方法。